Intravitreal Aflibercept 8 mg Injection in Patients with Neovascular Age-Related Macular Degeneration: 48-Week Results from the Phase 3 PULSAR Trial

Jean-François Korobelnik,[1] on behalf of the PULSAR study investigators

[1]CHU Bordeaux, Service d'Ophtalmologie, France; Univ. Bordeaux, INSERM, and Population Health Research Center, team LEHA, UMR 1219, F-33000, Bordeaux, France

Presented at the Retina Society 55th Annual Scientific Meeting; Pasadena, CA, USA; November 2–5, 2022

Note Regarding Forward-Looking Statements*

This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation EYLEA® (aflibercept) Injection and aflibercept 8 mg; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates (such as aflibercept 8 mg) and new indications for Regeneron's Products; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including the aflibercept 8 mg development program discussed in this presentation) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the study discussed in this presentation, on any potential regulatory approval of Regeneron's Products and Regeneron's Product Candidates (such as aflibercept 8 mg); safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates (such as aflibercept 8 mg) in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Bayer, to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA). A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2021 and its Form 10-Q for the quarterly period ended September 30, 2022. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events, or otherwise.

* This slide has been added for purposes of posting this presentation on Regeneron’s website.

Disclosures

pulsar
nAMD

- Jean-François Korobelnik is a consultant for Allergan-AbbVie, Apellis, Bayer, Janssen, NanoRetina, Novo Nordisk, Roche, Thea, Carl Zeiss Meditec
- The PULSAR study was sponsored by Bayer AG (Leverkusen, Germany) and co-funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Study disclosures: This study includes research conducted on human patients. Institutional Review Board approval was obtained prior to study initiation
- Medical writing support, under the direction of the author, was provided by ApotheCom and funded by Bayer Consumer Care AG, Basel, Switzerland, in accordance with Good Publication Practice (GPP3) guidelines (*Ann Intern Med* 2015;163:461–464)

Characteristics of Aflibercept 8 mg

pulsar
nAMD



- Novel intravitreal formulation delivers 8 mg in 70 µL injection (114.3 mg/mL)
- 4-times higher molar dose compared to aflibercept 2 mg is hypothesized to provide longer effective vitreal concentrations and enable a more sustained effect on VEGF signaling

Here, we present the results of the ongoing, randomized, double-masked, 96-week,
Phase 3 PULSAR trial in patients with treatment-naïve nAMD

nAMD, neovascular age-related macular degeneration; **PlGF**, placental growth factor; **VEGF**, vascular endothelial growth factor.

PULSAR Study Design

pulsar nAMD

Multicenter, randomized, double-masked study in patients with treatment-naïve nAMD
Randomized at baseline 1 (2q8) : 1 (8q12) : 1 (8q16)

2q8
Aflibercept 2 mg every 8 weeks after 3 initial monthly injections
n=336

8q12
Aflibercept 8 mg every 12 weeks after 3 initial monthly injections
n=335

8q16
Aflibercept 8 mg every 16 weeks after 3 initial monthly injections
n=338

Primary endpoint at Week 48
Mean change in BCVA (non-inferiority)

Key secondary endpoint at Week 16
Proportion of patients without IRF and SRF in the center subfield

End of study at Week 96

BCVA, best corrected visual acuity; **IRF**, intraretinal fluid; **SRF**, subretinal fluid.

PULSAR Study Sites

Global study conducted in 223 sites in 26 countries



Argentina (3 sites)
Canada (2 sites)
United States (52 sites)

Austria (3 sites)
Bulgaria (7 sites)
Czechia (7 sites)
Estonia (2 sites)
France (2 sites)
Georgia (4 sites)
Hungary (9 sites)
Israel (5 sites)
Italy (6 sites)

Latvia (3 sites)
Lithuania (3 sites)
Portugal (5 sites)
Russian Federation (2 sites)
Serbia (1 site)
Slovakia (5 sites)
Spain (9 sites)
Switzerland (3 sites)
Ukraine (4 sites)

Australia (5 sites)
China (29 sites)
Japan (44 sites)
Republic of Korea (7 sites)
Singapore (1 site)

PULSAR: Dosing Schedule in Year 1

pulsar nAMD

	Day 1	Wk 4	Wk 8	Wk 12	Wk 16	Wk 20	Wk 24	Wk 28	Wk 32	Wk 36	Wk 40	Wk 44	Wk 48
2q8	X	X	X		X	o	X	o	X	o	X	o	X
8q12	X	X	X		o	X	o	o	X	o	o	X	o
8q16	X	X	X		o	o	X	o	o	o	X	o	o

DRM in Year 1

- **Weeks 16 or 20**: patients on 8q12 or 8q16 and meeting DRM criteria had treatment interval shortened to q8
- **Week 24**: patients on 8q16 and meeting DRM criteria had treatment interval shortened to q12
- **Subsequent dosing visits**: patients on 8 mg and meeting DRM criteria had treatment interval shortened by 4 weeks
- Minimum interval for all patients was q8

DRM criteria for dosing interval shortening

>5-letter loss in BCVA from Week 12 BCVA due to persistent or worsening nAMD

AND

>25 µm increase in CRT from Week 12 or new onset foveal neovascularization or foveal hemorrhage

Stippled boxes = initial treatment phase; X=active injection; o=sham injections
Note: Table does not reflect all dosing options once a patient is shortened. No extension of interval was allowed in Year 1.
CRT, central retinal thickness; **DRM**, dose regimen modifications; **OCT**, optical coherence tomography; **Wk**, week.

PULSAR: Dosing Schedule in Year 1

pulsar nAMD

	Day 1	Wk 4	Wk 8	Wk 12	Wk 16	Wk 20	Wk 24	Wk 28	Wk 32	Wk 36	Wk 40	Wk 44	Wk 48
2q8	X	X	X		X	o	X	o	X	o	X	o	X
8q12	X	X	X		o	X	o	o	X	o	o	X	o
8q16	X	X	X		o	o	X	o	o	o	X	o	o

DRM in Year 1

- **Weeks 16 or 20**: patients on 8q12 or 8q16 and meeting DRM criteria had treatment interval shortened to q8
- **Week 24**: patients on 8q16 and meeting DRM criteria had treatment interval shortened to q12
- **Subsequent dosing visits**: patients on 8 mg and meeting DRM criteria had treatment interval shortened by 4 weeks
- Minimum interval for all patients was q8

DRM criteria for dosing interval shortening

>5-letter loss in BCVA from Week 12 BCVA due to persistent or worsening nAMD

AND

>25 µm increase in CRT from Week 12 or new onset foveal neovascularization or foveal hemorrhage

Stippled boxes = initial treatment phase; X=active injection; o=sham injections
Note: Table does not reflect all dosing options once a patient is shortened. No extension of interval was allowed in Year 1.
CRT, central retinal thickness; **DRM**, dose regimen modifications; **OCT**, optical coherence tomography; **Wk**, week.

Key Inclusion/Exclusion Criteria

pulsar nAMD

Inclusion Criteria

- Men or women ≥50 years of age with treatment-naïve nAMD
- Active subfoveal CNV, with a total area >50% of the total lesion area in the study eye
- Presence of IRF and/or SRF fluid in the central subfield on OCT
- BCVA of 78–24 letters (Snellen equivalent 20/32–20/320) with decreased vision due to nAMD

Exclusion Criteria

- Diabetic retinopathy, diabetic macular edema, or any retinal vascular disease other than nAMD in either eye
- Retinal pigment epithelial tears or rips, scar, fibrosis, or atrophy involving the central subfield in the study eye
- Uncontrolled glaucoma (IOP >25 mmHg despite anti-glaucoma medication) in the study eye
- Extra/periocular infection or inflammation in either eye at screening/randomization
- Uncontrolled blood pressure (SBP >160 mmHg or DBP >95 mmHg)

CNV, choroidal neovascularization; **DBP**, diastolic blood pressure; **IOP**, intraocular pressure; **SBP**, systolic blood pressure.

Patient Disposition at Week 48

	2q8	8q12	8q16	Total
# Randomized	337	336	338	1011
# Treated	99.7%	99.7%	100%	99.8%
# Completing Week 48	92.3%	94.6%	92.9%	93.3%
# Discontinued before Week 48	7.4%	5.1%	7.1%	6.5%
Reasons for discontinuation				
Withdrawal by subject	1.8%	1.5%	3.8%	2.4%
Adverse events	1.5%	0.6%	1.2%	1.1%
Death	1.5%	0.9%	0.3%	0.9%
COVID-19 related	0.6%	0.6%	0.6%	0.6%
Physician decision	0.3%	0.6%	0.6%	0.5%
Other[a]	1.8%	0.9%	0.6%	1.1%

[a]Includes 'lost to follow-up', 'lack of efficacy', and 'protocol deviation'. Categories were combined to maintain masking of individual patients.

Baseline Demographics

pulsar nAMD

	2q8	8q12	8q16	Total
N (FAS)	336	335	338	1009
Age (years)	74.2 (8.8)	74.7 (7.9)	74.5 (8.5)	74.5 (8.4)
Female (%)	56.0%	54.3%	53.3%	54.5%
Race (%)				
Asian	24.7%	22.1%	22.8%	23.2%
Black or African American	0.6%	0.6%	0	0.4%
White	74.1%	76.4%	76.9%	75.8%
Not reported	0.6%	0.6%	0.3%	0.5%
Hispanic or Latino (%)	3.6%	2.1%	2.7%	2.8%
Hypertension (%)	60.7%	66.3%	64.8%	63.9%

Data are mean (SD) unless otherwise indicated
FAS, full analysis set.

Baseline Characteristics of the Study Eye

pulsar nAMD

	2q8	8q12	8q16	Total
N (FAS)	336	335	338	1009
BCVA (ETDRS letters)	58.9 (14.0)	59.9 (13.4)	60.0 (12.4)	59.6 (13.3)
Snellen equivalent	20/63	20/63	20/63	20/63
20/32 (73 to 78 letters)	14.6%	12.5%	14.2%	13.8%
20/40 or worse (≤73 letters)	85.4%	87.5%	85.8%	86.2%
CRT (µm)	367 (134)	371 (124)	371 (133)	370 (130)
Total lesion area (mm^2)	6.9 (5.4)	6.4 (5.1)	6.9 (5.7)	6.7 (5.4)
Lesion type (%)				
Occult	57.1%	58.8%	55.0%	57.0%
Predominantly classic	21.1%	21.2%	19.8%	20.7%
Minimally classic	18.2%	16.7%	20.1%	18.3%

Data are mean (SD) unless otherwise indicated
ETDRS, Early Treatment of Diabetic Retinopathy Study.

PULSAR: 48-Week BCVA Results
Primary Endpoint Met in Both 8mg Groups

pulsar nAMD



	LS mean change from BL at Week 48 (MMRM)	Diff. in LS means vs 2q8	2-sided 95% CI	1-sided test for non-inferiority at 4-letter margin
2q8	7.0			
8q12	6.1	–0.97	–2.87, 0.92	p=0.0009
8q16	5.9	–1.14	–2.97, 0.69	p=0.0011

Observed values (censoring data post ICE); FAS: 2q8 n=336; 8q12 n=335; 8q16 n=338 (at baseline).
ICE, intercurrent events; **MMRM**, mixed model for repeated measurements.

Proportion of Patients Maintaining q12- and q16-Week Intervals Through Week 48

pulsar nAMD

83% of 8 mg patients maintained dosing intervals ≥12 weeks



8q12 n=316^



8q16 n=312^



All 8 mg n=628^

Values may not add to 100% due to rounding.
*Patients shortened based on DRM assessments at some point through Week 48.
^Patients completing Week 48.

Proportion of Patients Maintaining q12- and q16-Week Intervals Through Week 48





*Patients shortened based on DRM assessments at some point through Week 48.
^Patients completing Week 48.

Mean Number of Injections through Week 48

pulsar
nAMD



^Patients completing Week 48; 2q8 n=309; 8q12 n=316; 8q16 n=312.

Proportion of Patients Without Retinal Fluid in Center Subfield at Weeks 16 and 48

pulsar nAMD



Without retinal fluid defined as absence of IRF and SRF in center subfield.
LOCF (censoring data post ICE); FAS: 2q8 n=336; 8q12 n=335; 8q16 n=338.
†p=0.0015 8q12 vs 2q8; ‡p=0.0458 8q16 vs 2q8.

Time to a Fluid-Free Center Subfield

pulsar nAMD



Time to fluid-free retina is defined as the time of first injection until the time where a patient did not have any IRF or SRF in the central subfield for the first time (regardless of whether any retinal fluid was found again after that).
FAS: 2q8 n=336; 8q12 n=335; 8q16 n=338.

Central Retinal Thickness

pulsar nAMD



Observed values (censoring data post ICE); FAS: 2q8 n=336; 8q12 n=335; 8q16 n=338 (at baseline)

Most Frequent Ocular AEs Through Week 48

pulsar
nAMD

	2q8	8q12	8q16	All 8 mg
N (SAF)	336	335	338	673
Patients with ≥ 1 AE (%)*	38.7%	38.5%	37.6%	38.0%
Cataract	3.0%	3.6%	3.6%	3.6%
Intraocular pressure increased	2.1%	3.3%	2.7%	3.0%
Retinal hemorrhage	4.2%	3.3%	3.0%	3.1%
Subretinal fluid	3.3%	3.0%	1.5%	2.2%
Visual acuity reduced	6.0%	3.6%	5.3%	4.5%
Vitreous floaters	3.3%	1.2%	3.6%	2.4%

*Any ocular treatment-emergent event in the study eye.
AE, adverse event; **SAE**, serious adverse event; **SAF**, safety analysis set.

Intraocular Pressure Through Week 48

pulsar
nAMD

	2q8	8q12	8q16	All 8 mg
N (SAF)	336	335	338	673
Patients with IOP ≥ 35 mmHg pre- or post-injection (%)	0.3%	0.9%	0.3%	0.6%

Pre-injection IOP values were similar to baseline values at all timepoints through Week 48

Intraocular Inflammation Through Week 48

pulsar nAMD

	2q8	8q12	8q16	All 8 mg
N (SAF)	336	335	338	673
Patients with ≥ 1 IOI AE (%)*	0.6%	1.2%	0.3%	0.7%

No cases of endophthalmitis or occlusive retinal vasculitis

Reported IOI terms: chorioretinitis, iridocyclitis, iritis, vitreal cells, vitritis

*Treatment-emergent events.

Non-Ocular Safety Through Week 48

pulsar nAMD

	2q8	8q12	8q16	All 8 mg
N (SAF)	336	335	338	673
Patients with ≥ 1 AE (%)				
APTC events*	1.5%	0.3%	0.6%	0.4%
Hypertension events*	3.6%	4.8%	4.7%	4.8%
Non-ocular SAEs*	13.7%	10.1%	9.5%	9.8%
Deaths^	1.5%	0.9%	0.3%	0.6%

*Treatment-emergent events; ^All events. **APTC**, Anti-Platelet Trialists' Collaboration; **SAE**, serious adverse events.

PULSAR Summary: Primary and Key Secondary Endpoints Met

pulsar nAMD

- 8q12 and 8q16 groups had non-inferior BCVA compared to 2q8 at Week 48
- 8q12 and 8q16 combined had superior drying compared to 2q8 at Week 16



Observed values (censoring data post ICE).
FAS: 2q8 n=336; 8q12 n=335; 8q16 n=338 (at baseline).

p=0.0009 8q12 vs 2q8 95% CI (–2.87, 0.92)
p=0.0011 8q16 vs 2q8 95% CI (–2.97, 0.69)

NOTE: p-values for the one-sided non-inferiority test at a margin of 4 letters (based on adjusted means derived using an MMRM).

PULSAR: 48-Week Results
Majority of 8 mg Patients Maintained Randomized Intervals

pulsar nAMD

83% of 8 mg patients maintained dosing intervals ≥12 weeks



8q12 (n=316^)
Mean 6.1 injections



8q16 (n=312^)
Mean 5.2 injections



All 8 mg (n=628^)
Mean 5.6 injections

Values may not add to 100% due to rounding.
*Patients shortened based on DRM assessments at some point through Week 48. ^Patients completing Week 48.

PULSAR: 48-Week Safety Results

pulsar
nAMD

- Safety of aflibercept 8 mg consistent with the established safety profile of aflibercept 2 mg
- There were no new safety signals for aflibercept 8 mg or 2 mg and no cases of retinal vasculitis, occlusive retinitis or endophthalmitis
- There was no evidence of increased IOP with aflibercept 8 mg
- The incidence of APTC events was similar with aflibercept 8 mg and 2 mg